PURPOSE: More than 70% of Ewing tumors occur in the extremities and pelvis. This study identified factors influencing local control and functional outcomes after management with definitive radiotherapy (RT). PATIENTS AND METHODS: A total of 75 patients with a localized Ewing tumor of the extremity or pelvis were treated with definitive RT at the University of Florida between 1970 and 2006 (lower extremity tumors in 30, pelvic tumors in 26, and upper extremity tumors in 19). RT was performed on a once-daily (40%) or twice-daily (60%) basis. The median dose was 55.2 Gy in 1.8-Gy daily fractions or 55.0 Gy in 1.2-Gy twice-daily fractions. The median observed follow-up was 4.7 years. Functional outcome was assessed using the Toronto Extremity Salvage Score. RESULTS: The 10-year actuarial overall survival, cause-specific survival, freedom from relapse, and local control rate was 48%, 48%, 42%, and 71%, respectively. Of the 72 patients, 3 required salvage amputation. Inferior cause-specific survival was associated with larger tumors (81% for tumors <8 cm vs. 39% for tumors >/=8 cm, p <0.05). No patient characteristics or treatment variables were predictive of local failure. No fractures occurred in patients treated with hyperfractionation or with tumors of the distal extremities. Severe late complications were more frequently associated with use of <8-MV photons and fields encompassing the entire bone or hemipelvis. A significantly better Toronto Extremity Salvage Score was associated with a late-effect biologically effective dose of <91.7 Gy(3). CONCLUSIONS: Limb preservation was effectively achieved through definitive RT. Treating limited field sizes with hyperfractionated high-energy RT could minimize long-term complications and provides superior functional outcomes.
PURPOSE: More than 70% of Ewing tumors occur in the extremities and pelvis. This study identified factors influencing local control and functional outcomes after management with definitive radiotherapy (RT). PATIENTS AND METHODS: A total of 75 patients with a localized Ewing tumor of the extremity or pelvis were treated with definitive RT at the University of Florida between 1970 and 2006 (lower extremity tumors in 30, pelvic tumors in 26, and upper extremity tumors in 19). RT was performed on a once-daily (40%) or twice-daily (60%) basis. The median dose was 55.2 Gy in 1.8-Gy daily fractions or 55.0 Gy in 1.2-Gy twice-daily fractions. The median observed follow-up was 4.7 years. Functional outcome was assessed using the Toronto Extremity Salvage Score. RESULTS: The 10-year actuarial overall survival, cause-specific survival, freedom from relapse, and local control rate was 48%, 48%, 42%, and 71%, respectively. Of the 72 patients, 3 required salvage amputation. Inferior cause-specific survival was associated with larger tumors (81% for tumors <8 cm vs. 39% for tumors >/=8 cm, p <0.05). No patient characteristics or treatment variables were predictive of local failure. No fractures occurred in patients treated with hyperfractionation or with tumors of the distal extremities. Severe late complications were more frequently associated with use of <8-MV photons and fields encompassing the entire bone or hemipelvis. A significantly better Toronto Extremity Salvage Score was associated with a late-effect biologically effective dose of <91.7 Gy(3). CONCLUSIONS: Limb preservation was effectively achieved through definitive RT. Treating limited field sizes with hyperfractionated high-energy RT could minimize long-term complications and provides superior functional outcomes.
Authors: Dana C Baiu; Ian R Marsh; Alexander E Boruch; Ankita Shahi; Saswati Bhattacharya; Justin J Jeffery; Qianqian Zhao; Lance T Hall; Jamey P Weichert; Bryan P Bednarz; Mario Otto Journal: J Nucl Med Date: 2017-07-26 Impact factor: 10.057
Authors: Vivek Subbiah; Pete Anderson; Alexander J Lazar; Emily Burdett; Kevin Raymond; Joseph A Ludwig Journal: Curr Treat Options Oncol Date: 2009-06-17
Authors: Safia K Ahmed; R Lor Randall; Steven G DuBois; William S Harmsen; Mark Krailo; Karen J Marcus; Katherine A Janeway; David S Geller; Joel I Sorger; Richard B Womer; Linda Granowetter; Holcombe E Grier; Richard G Gorlick; Nadia N I Laack Journal: Int J Radiat Oncol Biol Phys Date: 2017-08-24 Impact factor: 7.038
Authors: Aimee C Talleur; Fariba Navid; Sheri L Spunt; M Beth McCarville; John Wu; Shenghua Mao; Andrew M Davidoff; Michael D Neel; Matthew J Krasin Journal: Int J Radiat Oncol Biol Phys Date: 2016-04-12 Impact factor: 7.038
Authors: Dimosthenis Andreou; Andreas Ranft; Georg Gosheger; Beate Timmermann; Ruth Ladenstein; Wolfgang Hartmann; Sebastian Bauer; Daniel Baumhoer; Henk van den Berg; P D Sander Dijkstra; Hans Roland Dürr; Hans Gelderblom; Jendrik Hardes; Lars Hjorth; Justus Kreyer; Jarmila Kruseova; Andreas Leithner; Sergiu Scobioala; Arne Streitbürger; Per-Ulf Tunn; Eva Wardelmann; Reinhard Windhager; Heribert Jürgens; Uta Dirksen Journal: Clin Orthop Relat Res Date: 2020-02 Impact factor: 4.755
Authors: Craig Gerrand; Nick Athanasou; Bernadette Brennan; Robert Grimer; Ian Judson; Bruce Morland; David Peake; Beatrice Seddon; Jeremy Whelan Journal: Clin Sarcoma Res Date: 2016-05-04